Labarai

Caesarea, Isra'ila, 13 ga Yuni, 2022 /PRNewswire/ — IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" ko "Kamfanin"), maganin cryotherapy mai sauƙin shiga ("IceCure (Shanghai) MedTech Co. ., Ltd. ("IceCure", wani reshe mallakar IceCure (Shanghai) MedTech Co., Ltd. Shanghai"), ya sanya hannu kan kwangila don gina tsarin cryoblation na IceSense3 tare da Shanghai Medtronic Zhikang Medical Devices Co., Ltd. ("Shanghai Medtronic"), wani reshe na Medtronic Corporation (NYSE: MDT) ("Medtronic") da Beijing Turing Medical Technology Co., Ltd. ("Turing") Ana sa ran za a samar da tsarin IceSense3 na farko a shekarar 2022.
Kamfanin Medtronic Shanghai zai zama kamfanin rarraba IceSense3 da na'urorin bincikensa da za a iya amfani da su a babban yankin kasar Sin na tsawon shekaru uku, tare da mafi karancin burin siyan su na dala miliyan 3.5 a wannan lokacin. Bugu da kari, a babban yankin kasar Sin, Shanghai Medtronic ba za ta zuba jari kai tsaye ko a kaikaice a ko a yi ciniki, sayarwa, tallatawa, tallatawa ko bayar da duk wani samfurin da ya yi gogayya da IceSense3 a lokacin yarjejeniyar rarrabawa da kuma bayan watanni shida (6). Turing zai dauki nauyin shigo da kaya, shigarwa da kuma bayan tallace-tallace na tsarin IceSense3 a babban yankin kasar Sin, yayin da Medtronic Shanghai zai kula da duk wani tallatawa, tallace-tallace da kuma wasu horo na kwararru.
Hukumar Kayayyakin Lafiya ta Ƙasa ta China ("NMPA") ta amince da IceSense3 System Console. IceCure ta nemi canjin takardar shaidar rajista don amincewa da na'urorin bincike da za a iya zubarwa waɗanda, idan an amince da su, za su ba kamfanin damar tallata na'urorin bincike na IceSense3 da za a iya zubarwa don amfanin kasuwanci, kuma IceCure tana sa ran samun amincewar NMPA ga na'urorin bincike nan da ƙarshen 2022.
"Shanghai Medtronic da Turing abokan hulɗa ne masu kyau a gare mu a babban yankin China, inda kasuwar fasahar cryoablation ke raguwa a yanzu. Muna ganin kyakkyawar dama don amfani da tsarin cryoablation na IceSense3 a babban yankin China, kasuwa da ke girma cikin sauri. wanda ke inganta sakamako," in ji Shugaba na IceCure Eyal Shamir. "A matsayin wani ɓangare na babban kamfanin na'urorin likitanci a duniya, Shanghai Medtronic tana da ƙwarewa da ikon kasuwa don ba da damar shiga cikin kasuwar IceSense3 cikin sauri don samar da lafiya, inganci da kuma magani mai araha ga cutar kansar nono da sauran alamu."
"IceCure tana da mafitar maganin ciwon daji mafi shahara a duniya," in ji Jing Yu, mataimakin shugaban ƙasa kuma babban manaja na Skull, Spine and Orthopedic Technologies a Medtronic Shanghai. Haɗin gwiwar da IceCure da Turing Medical za su ƙara wa layin samfuran Medtronic Shanghai a fannin tiyatar jijiyoyin cutar kansa. Muna fatan wannan haɗin gwiwar zai haɓaka amfani da maganin cryoablation na asibiti da kuma amfanar da ƙarin marasa lafiya da ciwon daji, kuma muna fatan yin aiki tare da ƙarin abokan hulɗa don hanzarta ɗaukar da kuma tura hanyoyin magance manyan ƙalubalen maganin ciwon daji. Sashen Lafiya na ƙasar Sin.
Shugaban kamfanin Turing Lin Youjia ya kara da cewa, "Tare da hadin gwiwar Shanghai Medtronic da IceCure, mun kuduri aniyar fara amfani da tsarin IceSense3 cikin sauri a babban yankin kasar Sin. Kasancewarmu a duk fadin kasar Sin a babban yankin kasar Sin yana tabbatar da cewa cibiyoyin kiwon lafiya sun sami tallafin fasaha mai inganci kuma suna amfani da tsarin IceSense3 na tsawon lokaci."
A ranar 12 ga Yuni, 2022 ("Ranar Fara Aiki"), IceCure Shanghai ta shiga yarjejeniyar tallace-tallace da rarrabawa ta musamman ("Yarjejeniyar Rarraba") tare da Shanghai Medtronic da Turing don IceSense3 da na'urorin bincike da za a iya zubarwa ("Kayayyaki") na tsawon lokaci na farko. A cikin watanni 36, mafi ƙarancin burin siyan wannan lokacin shine dala miliyan 3.5 ("Mafi ƙarancin Manufar Siyayya"). A ƙarƙashin yarjejeniyar rarrabawa, IceCure Shanghai za ta sayar da kayayyakin Turing kuma Turing za ta shigo da kayayyaki daga Isra'ila zuwa babban yankin China sannan ta sake sayar da su ga Medtronic Shanghai. Medtronic Shanghai za ta ɗauki alhakin, a tsakanin sauran abubuwa: (i) tallatawa da tallata samfurin a babban yankin China; (ii) gudanar da ayyukan ilimin likitanci na ƙwararru don samfurin a babban yankin China. Turing za ta ɗauki alhakin adana kayayyaki, jigilar kayayyaki, garanti, horo da sauran ayyuka na tallafi da bayan siyarwa.
A ƙarƙashin sharuɗɗan yarjejeniyar rarrabawa, Shanghai Medtronic tana da ikon tsawaita wa'adin yarjejeniyar rarrabawa na tsawon shekaru uku idan ta kai ga jimlar maƙasudin siye mafi ƙarancin shekaru uku, bisa ga yarjejeniyar sabuwar maƙasudin siye mafi ƙarancin shekaru. Ana iya dakatar da Yarjejeniyar Rarrabawa a wasu yanayi, gami da idan aka gaza biyan kuɗi, ko kuma aka gaza biyan kuɗi.
Bugu da ƙari, bisa ga sharuɗɗan Yarjejeniyar Masu Rarrabawa, IceCure Shanghai za ta ɗauki alhakin samun da kuma kiyaye duk wani izini na ƙa'ida ("Amincewa da Ka'idoji") da ake buƙata don tallatawa, tallatawa, rarrabawa, sayarwa da amfani da Kayayyakin a babban yankin China. NMPA, reshenta na gida, ko kowace hukumar gwamnati ("Hukumar Ka'idoji"). IceCure Shanghai ta sami amincewar ƙa'ida don IceSense3 System Console kuma tana buƙatar amincewar ƙa'ida don IceSense3 cryoprobe da za a iya zubarwa don hanyoyin kasuwanci cikin watanni tara daga ranar da yarjejeniyar rarrabawa ta fara aiki. Shanghai Medtronic tana da haƙƙin dakatar da yarjejeniyar rarrabawa idan IceCure Shanghai ba ta sami amincewar ƙa'ida don cryoprobes ba a lokacin.
IceCure Medical (NASDAQ: ICCM) (TASE: ICCM) ta haɓaka kuma ta tallata ProSense®, wani maganin cryoablative na ruwa mai ɗauke da sinadarin nitrogen don magance ciwace-ciwacen daji (marasa kyau da masu ciwon daji) tare da cryotherapy, wanda galibi ke niyya ga ciwon daji na nono, koda, ƙashi da huhu. Crayfish. Fasaharsa mai ƙarancin mamayewa tana ba da madadin lafiya da inganci ga tiyatar cire ciwon daji na asibiti, tare da ɗan gajeren lokacin aiki da kuma hanyar tiyata mai sauƙin yi. Zuwa yanzu, ana tallata tsarin kuma ana tallata shi a duk duniya don alamun da FDA ta amince da su kuma an amince da CE Mark a Turai.
Wannan sanarwar manema labarai ta ƙunshi kalamai masu hangen nesa a cikin ma'anar tanade-tanaden "amintaccen wurin tsaro" na Dokar Gyaran Shari'o'in Tsaro Masu Zaman Kansu na 1995 da sauran dokokin tsaro na tarayya. Kalmomi kamar "hasashe", "hasashe", "nufin", "shiri", "yi imani", "nufin", "ƙiyastawa" da makamantan maganganu ko bambance-bambancen irin waɗannan kalmomi an yi su ne don nufin kalamai masu hangen nesa. Misali, IceCure yana amfani da kalamai masu hangen nesa a cikin wannan sanarwar manema labarai lokacin da yake tattaunawa kan yarjejeniyoyin rarrabawa tare da Shanghai Medtronic da Turing, dabarun ƙa'idojin kamfanin, ayyukan kasuwanci, da damar kasuwa don tsarin cryoablation na kamfanin a babban yankin China. Saboda irin waɗannan kalamai suna da alaƙa da abubuwan da za su faru nan gaba kuma sun dogara ne akan tsammanin IceCure na yanzu, suna fuskantar haɗari da rashin tabbas daban-daban, kuma ainihin sakamakon, aikin ko nasarorin IceCure na iya bambanta da waɗanda aka bayyana ko aka nuna ta cikin wannan sanarwar manema labarai. Akwai manyan bambance-bambance. . Kalamai masu hangen nesa da ke ƙunshe ko kuma waɗanda aka nuna a cikin wannan sanarwar manema labarai suna fuskantar wasu haɗari da rashin tabbas, waɗanda da yawa daga cikinsu ba su da ikon mallakar Kamfanin, gami da waɗanda aka bayyana a cikin sashin "Abubuwan Haɗari" na Rahoton Shekara-shekara na Kamfanin kan Form 20-F da aka shigar a SEC har zuwa 1 ga Afrilu, 2022 na shekarar da ta ƙare a ranar 31 ga Disamba, 2021, wanda ake samu a gidan yanar gizon SEC a www.sec.gov. Kamfanin ba ya ɗaukar wani wajibi na sabunta waɗannan kalamai don gyara ko canje-canje bayan ranar wannan sanarwar manema labarai, sai dai idan doka ta buƙaci yin hakan.